Smad protein expression and activation in transforming growth factor-β refractory human squamous cell carcinoma cells

Oncology Research

Volumn 12, Issue 3, 2000, Pages 157-167

  Yan, Wu ^a   Vellucci, Vincent F ^a   Reiss, Michael ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Head neck cancer; Mutation; Receptor; Smad; Squamous cell carcinoma; Transforming growth factor

Indexed keywords

DNA BINDING PROTEIN; SMAD2 PROTEIN; SMAD2 PROTEIN, HUMAN; SMAD4 PROTEIN; SMAD4 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTICLE; CELL CULTURE; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; DNA-BINDING PROTEINS; HUMANS; PHOSPHORYLATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD4 PROTEIN; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0034568227     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504001108747639     Document Type: Article

References (84)

1. Reiss, M.; Stash, E. B. High frequency of resistance of human squamous carcinoma cells to the anti-proliferative action of transforming growth factor-β. Cancer Commun. 2:363-369; 1990.
2. Fynan, T. M.; Reiss, M. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit. Rev. Oncog. 4:493-540; 1993.
3. Reiss, M. Transforming growth factor-beta and cancer: A love-hate relationship? Oncol. Res. 9:447-457; 1997.
4. Heldin, C.-H.; Miyazono, K.; ten Dijke, P. TGF-β signaling from cell membrane to nucleus through SMAD proteins. Nature 390: 465-471; 1997.
5. kipl, a cyclin-cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8:9-22; 1994.
6. Hannon, G. J.; Beach, D. p151NK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-261; 1994.
7. Datto, M. B.; Li, Y.; Panus, J. F.; Howe, D. J.; Xiong, Y.; Wang, X. F. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA 92:5545-5549; 1995.
8. Ewen, M. E.; Sluss, H. K.; Whitehouse, L. L.; Livingston, D. M. TGF-β inhibition of cdk4 synthesis is linked to cell cycle arrest. Cell 74:1009-1020; 1993.
9. Iavarone. A.; Massagué, J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15. Nature 387:417-422; 1997.
10. Derynck, R.; Zhang, Y.; Feng, X.-H. Smads: Transcriptional activators of TGF-β responses. Cell 95:737-740; 1998.
11. Reiss, M. TGF-β and cancer. Microbes Infect. 1:1327-1347; 1999.
12. Park, K.; Kim, S. J.; Bang, Y. J.; Park, J. G.; Kim, N. K.; Roberts, A. B.; Sporn, M. B. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: Correlation with sensitivity to growth inhibition by TGF-beta. Proc. Natl. Acad. Sci. USA 91:8772-8776; 1994.
13. Sun, L.; Wu, G.; Willson, J. K.; Zborowska, E.; Yang, J.; Rajkarunanayake, I.; Wang, J.; Gentry, L. E.; Wang, X. F.; Brattain, M. G. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J. Biol. Chem. 269:26449-26455; 1994.
14. Mycroff, L. L.; Parsons, R.; Kim, S.-J.; Hedrick, L.; Cho, K. R. Orth, K.; Mathis, M.; Kinzler, K. W.; Lutterbaugh, J.; Park, K.; Bang, Y.-J.; Lee, H. Y.; Park, J.-G.; Lynch, H. T.; Roberts, A. B.; Vogelstein, B.; Markowitz, S. D. A transforming growth factor β type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 55:5545-5547; 1995.
15. Kalkhoven, E.; Roelen, B. A.; de Winter, J. P.; Mummery, C. L.; van den Eijnden-van Raaij, A. J.; van der Saag, P. T.; van der Burg, B. Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ. 6:1151-1161; 1995.
16. de Jonge, R. R.; Garrigue-Antar, L.; Vellucci, V. F.; Reiss, M. Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells. Oncol. Res. 9:89-98; 1997.
17. Yang, H. K.; Kang, S.H.; Kim, Y. S.; Won, K.; Bang, Y. J.; Kim, S. J. Truncation of the TGF-beta type II receptor gene results in insensitivity to TGF-beta in human gastric cancer cells. Oncogene 18:2213-2219; 1999.
18. Grady, W. M.; Myeroff, L. L.; Swinler, S. E.; Rajput, A.; Thiagalingam, S.; Lutterbaugh, J. D.; Neumann, A.; Brattain, M. G.; Chang, J.; Kim, S. J.; Kinzler, K. W.; Vogelstein, B.; Willson, J. K.; Markowitz, S. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res. 59:320-324; 1999.
19. Garrigue-Antar, L.; Souza, R. F.; Vellucci, V. F.; Meltzer, S. J.; Reiss, M. Loss of transforming growth factor-beta type II receptor gene expression in primary human esophageal cancer. Lab. Invest. 75:263-272; 1996.
20. Azuina, M.; Yuki, T.; Tamatani, T.; Motegi, K.; Yoshida, H.; Sato, M. Lack of expression of transforming growth factor-beta type II receptor associated with malignant progression in human salivary gland cell clones. Int. J. Cancer 66:802-805; 1996.
21. Guo, Y.; Jacobs, S. C.; Kyprianou, N. Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-betal) type I and type II receptors in human prostate cancer. Int. J. Cancer 71:573-579; 1997.
22. Lazzereschi, D.; Ranieri, A.; Mincione, G.; Taccogna, S.; Nardi, F.; Colletta, G. Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein. Cancer Res. 57:2071-2076; 1997.
23. Chen, T.; Carter, D.; Garriguc-Antar, L.; Reiss, M. Transforming growth factor-β type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res. 58:4805-4810; 1998.
24. Goggins, M.; Shekher, M.; Turnacioglu, K.; Yeo, C. J.; Hruban, R. H.; Kern, S. E. Genetic alterations of the transforming growth factor β receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res. 58:5329-5332; 1998.
25. Schiemann, W. P.; Pfeifer, W. M.; Levi, E.; Kadin, M. E.; Lodish, H. F. A Deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood 94: 2854-2861; 1999.
26. Hahn, S. A.; Schutte, M.; Hoque, A. T.; Moskaluk, C. A.; da Costa, L. T.; Rozenblum, E.; Weinstein, C. L.; Fischer, A.; Yeo, C. J.; Hruban, R. H.; Kern, S. E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-353; 1996.
27. Kim, S. K.; Fan, Y.; Papadimitrikopoulou, V.; Clayman, G.; Hittelman, W. N.; Hong, W. K.; Lotan , R.; Mao, L. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res. 56:2519-2521; 1996.
28. Nagatake, M.; Takagi, Y.; Osada, H.; Uchida, K.; Mitsudomi, T.; Saji, S.; Shimotaka, K.; Takahashi, T.; Takahashi, T. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res. 56:2718-2720; 1996.
29. Schutte, M.; Hruban, R. H.; Hedrick, L.; Cho, K. R.; Nadasdy, G. M.; Weinstein, C. L.; Bova, G. S.; Isaacs, W. B.; Cairns, P.; Nawroz, H.; Sidransky, D.; Casero, R. A., Jr.; Meltzer, P. S.; Hahn, S. A.; Kern, S. E. DPC4 gene in various tumor types. Cancer Res. 56:2527-2530; 1996.
30. Reiss, M.; Santoro, V.; De Jonge, R. R.; Vellucci, V. F. Transfer of chromosome 18 into human head and neck squamous carcinoma cells: Evidence for tumor suppression by Smad4/DPC4. Cell Growth Differ. 8:407-415; 1997.
31. Hahn, S. A.; Bartsch, D.; Schroers, A.; Galehdari, H.; Becker, M.; Ramaswamy, A.; Schwarte-Waldhoff, I.; Maschek, H.; Schmiegel, W. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res. 58:1124-1126; 1998.
32. Eppert, K.; Scherer, S. W.; Ozcelik, H.; Pirone, R.; Hoodless, P.; Kim, H.; Tsui, L. C.; Bapat, B.; Gallinger, S.; Andrulis, I. L.; Thomsen, G. H.; Wrana, J. L.; Attisano, L. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86:543-552; 1996.
33. Thiagalingam, S.; Lengauer, C.; Leach, F. S.; Schutte, M.; Hahn, S. A.; Overhauser, J.; Willson, J. K.; Markowitz, S.; Hamilton, S. R.; Kern, S. E.; Kinzler, K. W.; Vogelstein, B. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat. Genet. 13:343-346; 1996.
34. Riggins, G. J.; Kinzler, K. W.; Vogelstein, B.; Thiagalingam, S. Frequency of Smad gene mutations in human cancers. Cancer Res. 57:2578-2580; 1997.
35. Wang, D.; Kanuma, T.; Takama, F.; Mizumuma, H.; Ibuki, Y.; Wake, N.; Mogi, A.; Shitara, Y.; Hagiwara, K.; Takenoshita, S. Mutation analysis of the Smad3 gene in human ovarian cancers. Int. J. Oncol. 15:949-953; 1999.
36. Wilentz, R. E.; lacobuzio-Donahue, C. A.; Argani, P.; McCarthy, D. M.; Parsons, J. L.; Yeo, C. J.; Kern, S. E.; Hruban, R. H. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 60:2002-2006; 2000.
37. Wilentz, R. E.; Su, G. H.; Dai, J. L.; Sparks, A. B.; Argani, P.; Sohn, T. A.; Yeo, C. J.; Kern, S. E.; Hruban, R. H. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation. Am. J. Pathol. 156:37-43; 2000.
38. Giard, D. J.; Aaronson, S. A.; Todaro, G. J.; Arnstein, P.; Kersey, J. H.; Dosik, H.; Parks, W. P. In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J. Natl. Cancer Inst. 51:1417-1423; 1973.
39. Fabricant, R. N.; DeLarco, J. E.; Todaro, G. J. Nerve growth factor receptors on human melanoma cells in culture. Proc. Natl. Acad. Sci. USA 74:565-569; 1977.
40. Fogh, J.; Fogh, J. M.; Orfeo, T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59:221-226; 1977.
41. Auersperg, N.; Hawryluk, A. P. Chromosome observations on three epithelial cell cultures derived from carcinomas of the cervix. J. Natl. Cancer Inst. 28:605-628; 1962.
42. Rangan, S. R. A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer 29:117-121; 1972.
43. Hu, C.-P.; Hsian-Guey, H.; Kwang-y, C.; Pei-yen, W.; Ching-i, W.; Chih-yi, C.; Szecheng, J. L.; Kuang-dong, W.; Chungming, C. Biologic properties of three newly established human esophageal carcinoma cell lines. J. Natl. Cancer Inst. 75:577-581; 1984.
44. Reiss, M.; Pitman, S. W.; Sartorelli, A. C. Modulation of the terminal differentiation of human squamous carcinoma cells in vitro by all-trans retinoic acid. J. Natl. Cancer Inst. 74:1015-1023; 1985.
45. Pirisi, L.; Yasumoto, S.; Feller, M.; Doniger, J.; DiPaolo, J. A. Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA. J. Virol. 61:1061-1066; 1987.
46. Chen, T. R. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp. Cell Res. 104: 255-262; 1977.
47. Abdollah, S.; Macias-Silva, M.; Tsukazaki, T.; Hayashi, H.; Attisano, L.; Wrana, J. L. TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J. Biol. Chem. 272:27678-27685; 1997.
48. Souchelnytskyi, S.; Tamaki, K.; Engstrom, U.; Wernstedt, C.; ten Dijke, P.; Heldin, C. H. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J. Biol. Chem. 272:28107-28115; 1997.
49. Liu, X.; Sun, Y.; Constantinescu, S. N.; Karam, E.; Weinberg, R. A.; Lodish, H. F. Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc. Natl. Acad. Sci. USA 94:10669-10674; 1997.
50. DiGiovanna, M. P.; Roussel, R. R.; Stern, D. F. Production of antibodies that recognize specific tyrosine phosphorylated peptides. In: Current protocols in molecular biology, vol. unit 18.6. New York: John Wiley & Sons; 1996:1-19.
51. Chomczynski, P.; Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159; 1987.
52. Wrana, J. L.; Attisano, L.; Creamo, J.; Zentella, A.; Doody, J.; Laiho, M.; Wang, X.-F.; Massagué, J. TGF-β signals through a heteromeric protein kinase receptor complex. Cell 71:1003-1014; 1992.
53. De, M.; Yan, W.; de Jonge, R. R.; Garrigue-Antar, L.; Vellucci, V. F.; Reiss, M. Functional characterization of transforming growth factor beta type II receptor mutants in human cancer. Cancer Res. 58:1986-1992; 1998.
54. Reiss, M.; Mu-oz-Antonia, T.; Cowan, J. M.; Wilkins, P. C.; Zhou, Z.-L.; Vellucci, V. F. Resistance of human squamous carcinoma cells to the anti-proliferative effect of transforming growth factor-β is a recessive phcnotype. Proc. Natl. Acad. Sci. USA 90: 6280-6284; 1993.
55. Lagna, G.; Hata, A.; Hemmati-Brivanlou, A.; Massague, J. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature 383:832-836; 1996.
56. Zhang, Y.; Musci, T.; Derynck, R. The tumor suppressor Smad4/ DPC4 as a central mediator of Smad function. Curr. Biol. 7:270-276; 1997.
57. Wu, R. Y.; Zhang, Y.; Feng, X. H.; Derynck, R. Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of Smad3 and Smad4/DPC4. Mol. Cell. Biol. 17:2521-2528; 1997.
58. Macias-Silva, M.; Abdollah, S.; Hoodless, P. A.; Pirone, R.; Attisano, L.; Wrana, J. L. MADR2 is a substrate of the TGF-β receptor and its phosphorylation is required for nuclear accumulation and sigaling. Cell 87:1215-1224; 1996.
59. Hata, A.; Lo, R. S.; Wotton, D.; Lagna, G.; Massagué, J. Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. Nature 388:82-87; 1997.
60. Nakao, A.; Imamura, T.; Souchelnytskyi, S.; Kawabata, M.; Ishisaki, A.; Oeda, E.; Tamaki, K.; Hanai, J.; Heldin, C. H.; Miyazono, K.; ten Dijke, P. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 16:5353-5362; 1997.
61. Zhang, Y.; Feng, X.-H.; Wu, R.-Y.; Derynck, R. Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature 383:168-172; 1996.
62. Korchynskyi, O.; Landstrom, M.; Stoika, R.; Funa, K.; Heldin, C. H.; ten Dijke, P.; Souchelnytskyi, S. Expression of Smad proteins in human colorectal cancer. Int. J. Cancer 82:197-202; 1999.
63. Garrigue-Antar, L.; Munoz-Antonia, T.; Antonia, S. J.; Gesmonde, J.; Vellucci, V. F.; Reiss, M. Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. Cancer Res. 55:3982-3987; 1995.
64. Munoz-Antonia, T.; Li, X.; Reiss, M.; Jackson, R.; Antonia, S. A mutation in the transforming growth factor beta type II receptor gene promoter associated with loss of gene expression. Cancer Res. 56:4831-4835; 1996.
65. Piek, E.; Westermark, U.; Kastemar, M.; Heldin, C. H.; van Zoelen, E. J.; Nister, M.; Ten Dijke, P. Expression of transforming-growth-factor (TGF)-beta receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF- betal. Int. J. Cancer 80:756-763; 1999.
66. Chen, X.; Weisberg, E.; Fridmacher, V.; Watanabe, M.; Naco, G.; Whitman, M. Smad4 and FAST-1 in the assembly of activinresponsive factor. Nature 389:85-89; 1997.
67. Labbé, E.; Silvestri, C.; Hoodless, P. A.; Wrana, J. L.; Attisano, L. Smad2 and Smad3 positively and negatively regulate TGF-β-dependent transcription through the forkhead DNA-binding protein FAST2. Mol. Cell 2:109-120; 1998.
68. Zhou, S.; Zawel, L.; Lengauer, C.; Kinzler, K. W.; Vogelstein, B. Characterization of human FAST-1, a TGF-β and activin signal transducer. Mol. Cell 2:121-127; 1998.
69. Nagarajan, R. P.; Liu, J.; Chen, Y. Smad3 inhibits transforming growth factor-beta and activin signaling by competing with Smad4 for FAST-2 binding. J. Biol. Chem. 274:31229-31235; 1999.
70. INK4B through an Sp1 consensus site. J. Biol. Chem. 270:26750-26753; 1995.
71. Li, C. Y.; Suardet, L.; Little, J. B. Potential role of WAF1/Cip1/ p21 as a mediator of TGF-beta cytoinhibitory effect. J. Biol. Chem. 270:4971-4974; 1995.
72. Yingling, J. M.; Datto, M. B.; Wong, C.; Frederick, J. P.; Liberati, N. T.; Wang, X. F. Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein. Mol. Cell. Biol. 17:7019-7028; 1997.
73. Dai, J. L.; Schutte, M.; Bansal, R. K.; Wilentz, R. E.; Sugar, A. Y.; Kern, S. E. Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells. Mol. Carcinog. 26:37-43; 1999.
74. Sirard, C.; Kim, S.; Mirtsos, C.; Tadich, P.; Hoodless, P. A.; Iti, A.; Maxson, R.; Wrana, J. L.; Mak, T. W. Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor beta-related signaling. J. Biol. Chem. 275:2063-2070; 2000.
75. Rodeck, U.; Nishiyama, T.; Mauviel, A. Independent regulation of growth and SMAD-mediated transcription by transforming growth factor β in human melanoma cells. Cancer Res. 59:547-550; 1999.
76. Fero, M. L.; Rivkin, M.; Tasch, M.; Porter, P.; Carow, C. E.; Firpo, E.; Polyak, K.; Tsai, L. H.; Broudy, V.; Perlmutter, R. M.; Kaushansky, K.; Roberts, J. M. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigcnesis, and female sterility in p27(Kip1)-deficient mice. Cell 85:733-744; 1996.
77. Missero, C.; Di Cunto, F.; Kiyokawa, H.; Koff, A.; Dotto, G. P. The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev. 10:3065-3075; 1996.
78. Pietenpol, J. A.; Munger, K.; Howley, P. M.; Stein, R. W.; Moses, H. L. Factor-binding element in the human c-myc promoter involved in transcriptional regulation by transforming growth factor beta 1 and by the retinoblastoma gene product. Proc. Natl. Acad. Sci. USA 88:10227-10231; 1991.
79. Tavtigian, S. V.; Zabludoff, S. D.; Wold, B. J. Cloning of mid-G1 serum response genes and identification of a subset regulated by conditional myc expression. Mol. Biol. Cell 5:375-388; 1994.
80. Reiss, M.; Dibble, C. L.; Narayanan, R. Stable transfection of c-myc sequences into mouse keratinocytes: Amplification of the response to epidermal growth factor. J. Invest. Dermatol. 93:136-141; 1989.
81. Alexandrow, M. G.; Kawabata, M.; Aakre, M.; Moses, H. L. Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta 1. Proc. Natl. Acad. Sci. USA 92: 3239-3243; 1995.
82. Okamoto, A.; Jiang, W.; Kim, S. J.; Spillare, E. A.; Stoner, G. D.; Weinstein, I. B.; Harris, C. C. Overexpression of human cyclin D1 reduces the transforming growth factor beta (TGF-beta) type II receptor and growth inhibition by TGF- beta 1 in an immortalized human esophageal epithelial cell line. Proc. Natl. Acad. Sci. USA 91:11576-11580; 1994.
83. Volm, M.; Koomagi, R.; Rittgen, W. Clinical implications of cyclins, cyclin-dependent kinases, RB and E2F1 in squamous-cell lung carcinoma. Int. J. Cancer 79:294-299; 1998.
84. Reiss, M.; Stash, E. B.; Vellucci, V. F.; Zhou, Z.-L. Activation of the autocrine transforming growth factor alpha pathway in human squamous carcinoma cells. Cancer Res. 51:6254-6262; 1991.